couter

ACIUAC Immune S.A.

Health CarePharmaceuticals

The Read

7%, including a modest 0% move around June 30 earnings.
Nov 10, 2026 — Q3 2026 Earnings Release
Chart by TradingView

The schedule

  • Tue10Nov
  • Sun14Feb
  • Fri14May
  • Wed4Aug

Past

  • Wed5Aug

    Actual outcome: Bull · $2.36 at outcome

    ACIU beat earnings estimates with an EPS of $0.019, matching the estimate, and provided positive guidance on its pipeline and cash runway. The company highlighted progress in its Phase 2 trial for ACI-7104 in Parkinson's disease, which supported the stock's rally. The price movement reflects optimism around near-term clinical catalysts and the company's financial outlook.

    Quarterly earnings update focusing intensely on remaining liquidity and burn rate.

  • Mon20Jul

    Actual outcome: Mixed · $2.20 at outcome

    ACIU did not announce a definitive strategic equity financing or partnership by the target date, leaving its critical near-term liquidity overhang unresolved. Without a clear resolution to its funding needs, the stock experienced a muted, slightly negative reaction as investors remained on the sidelines awaiting further clarity on the company's capital strategy.

    Strategic equity financing or partnership announcement to address the critical near-term liquidity overhang.

  • Tue30Jun

    Actual outcome: Bull · $2.54 at outcome

    AC Immune reported positive interim 12-month data from the Phase 1b/2 ABATE trial of ACI-24 in prodromal Alzheimer's disease, showing the active immunotherapy was generally safe and well-tolerated across the first three cohorts. The trial successfully demonstrated an anti-Abeta antibody dose-response with antibodies detected at all dose levels, validating the clinical proof-of-concept and driving the stock 6.7% higher.

    Key clinical proof-of-concept readout for the ABATE AD3 cohort, carrying significant binary risk for the company's valuation.

  • Fri15May

    Actual outcome: Bear · $2.40 at outcome

    AC Immune reported in-line Q1 2026 earnings with an EPS of -$0.15, but the stock faced downward pressure following the announced retirement of long-time co-founder and CEO Dr. Andrea Pfeifer. Despite presenting positive Phase 1 data for its TDP-43 PET Tracer in ALS patients shortly after, the leadership transition and lack of major commercial catalysts led investors to price in greater uncertainty, driving shares well below the $3.00 bear floor.

    Q1 2026 earnings and an R&D update around $3.40 will test how much of AC Immune’s recent strength is justified by partnering revenue, cash burn, and visibility on Alzheimer’s and Parkinson’s programs; a constructive print with stable cash and clear milestones could support a move toward $3.90, while weak revenue and higher-than-expected operating cash outflows could see the stock fade back toward $3.90 as investors price in greater financing risk.